Renoprotective effects, including a 29–38% risk reduction in chronic kidney disease compared to DPP-4i and sulfonylureas, mirror the hemodynamic benefits observed in trials such as REWIND35 and FLOW6, where GLP-1 RA attenuated albuminuria progression among other clinical benefits. The gene discussed is GLP1R; the disease is chronic kidney disease.